Summary of ONCOSEC MEDICAL INC

Quotes & Info

Enter Symbol(s):
e.g. YHOO, ^DJI

Symbol Lookup | Financial Search

ONCS > SEC Filings for ONCS > Form 8-K on 28-Nov-2012

All Recent SEC Filings

Show all filings for ONCOSEC MEDICAL INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for ONCOSEC MEDICAL INC

28-Nov-2012

Other Events

Item 8.01Other Events.

Effective November 26, 2012, Adil Daud, M.D., Shailender Bhatia, M.D., and Weiyun Ai, M.D. transferred their rights under the Investigational New Drug (IND) program for the use of ImmunoPulse in melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma to OncoSec Medical Incorporated (the "Company"). The transfer of these INDs permits the Company to assume exclusive sponsorship for ongoing and future clinical trials involving ImmunoPulse for the treatment of melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. Previously, clinical trials involving ImmunoPulse have been investigator-sponsored.

Add ONCS to Portfolio

Set Alert

Email to a Friend

Get SEC Filings for Another Symbol: Symbol Lookup

Quotes & Info for ONCS - All Recent SEC Filings

Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial Sign Up Now

Copyright © 2013 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.